Finzati - Logo
CLCS logo

Cell Source, Inc.

CLCS • Biotechnology
$0.49
▼ -0.00 (-0.01%)
Current price
EarningsLatest report: Dec 31, 2024
WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$21.99M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Weak liquidity · 0.02Weak profitability
Financial data as of: Dec 31, 2024, 12:00 AM UTCLast earnings update: Dec 31, 2024, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.49
Change-0.01%
Shares Out45.04M
Market Cap$21.99M
Enterprise Value$31.99M
52W Range0.23 - 2.25
Beta-157.98
P/E-4.61
P/B-1.17
P/FCF-8.19
EV/EBITDA-8.90
EV/FCF-11.92

Investment DNA

How strong this company looks for long-term investors

33
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
20/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
50/100
Why this score▼
Weak liquidity · 0.02Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 5/1/2014
Industry: Biotechnology
P/B i: -1.17
Debt / Equity i: -0.54
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score4 / 20
Debt / Equity: -0.54
Current Ratio: 0.02
Quick Ratio: 0.02
Status: HighRisk

Warnings

  • Weak Liquidity
  • Weak quick ratio

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected
Verstraete George
Transaction: 03/10/2022
OTHER
Change
0
Price
Not reported
Filing
04/21/2022
Type
OTHER
Soave Darlene
Transaction: 08/09/2021
BUY
Change
+800,000
Price
$1.25
Filing
08/11/2021
Type
BUY
FRIEDMAN BENZION ABRAHAM
Transaction: 06/30/2021
BUY
Change
+19,440
Price
$0.75
Filing
07/07/2021
Type
BUY